By helping women become aware of ovarian cancer symptoms, it is OCC’s hope that we will be able to make a difference and help women receive early diagnosis. Join us to provide awareness, education, and also support for women with this disease.
Recent News:
EMERGING OVARIAN RESEARCH
Fall 2012
This year, a phase II randomized study investigated the use of paclitaxel and carboplatin bevacizumab (Avastin) as a primary treatment and continuing as a maintenance drug in platinum resistant ovarian cancer. The results were that progression free survival (PFS) increased 3.6 months to 6.7 months, a 52 percent improvement. Overall survival (OS) data will be available in 2013.
Fall 2012
This year, a phase II randomized study investigated the use of paclitaxel and carboplatin bevacizumab (Avastin) as a primary treatment and continuing as a maintenance drug in platinum resistant ovarian cancer. The results were that progression free survival (PFS) increased 3.6 months to 6.7 months, a 52 percent improvement. Overall survival (OS) data will be available in 2013.
TARGETED THERAPIES
July 2012
During a discussion about targeted therapies generally failing to show an improvement in overall survival (OS), some skepticism was expressed regarding targeted therapies in ovarian cancer. Because the results of genetic studies show that each case of ovarian cancer is genetically unique, the provocation conclusion to this discussion was to halt Phase III trials in ovarian cancer and researchers focus on prevention, immunotherapy and tumor initiation.
July 2012
During a discussion about targeted therapies generally failing to show an improvement in overall survival (OS), some skepticism was expressed regarding targeted therapies in ovarian cancer. Because the results of genetic studies show that each case of ovarian cancer is genetically unique, the provocation conclusion to this discussion was to halt Phase III trials in ovarian cancer and researchers focus on prevention, immunotherapy and tumor initiation.
MAINTENANCE TREATMENT
Fall 2012
A trial used Olaparib as a maintenance drug to treat ovarian cancer in women with or without a BRCA mutation. The trial showed an increase in progression free survival (PFS) from 9.6 months to 12.2 months (HR .35); but no increase in overall survival (OS) and no change in tumor size.
Fall 2012
A trial used Olaparib as a maintenance drug to treat ovarian cancer in women with or without a BRCA mutation. The trial showed an increase in progression free survival (PFS) from 9.6 months to 12.2 months (HR .35); but no increase in overall survival (OS) and no change in tumor size.
IMPROVING PROVIDER COMMUNICATION
July 2012
Another panel discussed the high cost of cancer care and what providers can do to bring that cost down without sacrificing quality. The panel urged providers to adhere to guidelines and have conversations, early on, about the goals of the treatment, the use of palliative care, living wills and hospice.
July 2012
Another panel discussed the high cost of cancer care and what providers can do to bring that cost down without sacrificing quality. The panel urged providers to adhere to guidelines and have conversations, early on, about the goals of the treatment, the use of palliative care, living wills and hospice.
VOLUNTEER APPRECIATION
September 2012
A special thanks to all the volunteers who helped at the many OCC events and at the OCC office. OCC greatly appreciates the volunteers who made the 14th Annual Walk Run a success. Special thanks to the Captains: Barbara Ferreira, Eva Simon, Alan Wohl, Paul Johnson, Leslie Dorfman, Greer Saunders, Lorie Lieberman, Dave DelPrete and Consuelo Costin.
September 2012
A special thanks to all the volunteers who helped at the many OCC events and at the OCC office. OCC greatly appreciates the volunteers who made the 14th Annual Walk Run a success. Special thanks to the Captains: Barbara Ferreira, Eva Simon, Alan Wohl, Paul Johnson, Leslie Dorfman, Greer Saunders, Lorie Lieberman, Dave DelPrete and Consuelo Costin.
5TH ANNUAL LUNCH & LEARN
APRIL 2012
The 5th Annual Lunch & Learn Symposium was a huge success. The distinguished keynote speakers included: Dr. Robin Eisner, MD PhD of Gynecologic Oncology & Gynecology at UCLA; Dr. Ilana Cass, MD at the Cedars-Sinai Division of Gynecologic Oncology; and Jesse Brune Private Chef of Beverly Hills speaking on nutrition.
APRIL 2012
The 5th Annual Lunch & Learn Symposium was a huge success. The distinguished keynote speakers included: Dr. Robin Eisner, MD PhD of Gynecologic Oncology & Gynecology at UCLA; Dr. Ilana Cass, MD at the Cedars-Sinai Division of Gynecologic Oncology; and Jesse Brune Private Chef of Beverly Hills speaking on nutrition.
The Ovarian Cancer Coalition of Greater California is a nonprofit 501(c) grassroots organization founded in 2001 to help women to be aware of ovarian cancer and advocate for early detection.